

#28  
Suppl. PTO  
w/ attach.  
PATENT  
10/9/00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: **Harris et al.**

Group Art Unit No.: **1651**

TECH CENTER 1600 RECEIVED  
99 DEC 15 PM 2:25  
10/9/00

Serial No.: **08/259,413**

Examiner: **H. Lilling**

Filed: **June 14, 1994**

For: **PEGYLATION REAGENTS AND  
COMPOUNDS FORMED THEREWITH**

Docket No.: **S-210C**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. § 1.56 and 1.97(c), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Copies of the listed documents are enclosed.

This Information Disclosure Statement is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Action (after the Rule 1.129(a) Request was filed on August 16, 1999) or a Notice of Allowance. Please charge Deposit Account No. 01-0519, in the name of Amgen Inc., in the amount of \$240.00, which is the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c). **An original and one copy of this paper are enclosed.**

PCT Publication No. WO 90/04413 A1 is not in English. That document claims the same priority application as United States Patent No. 5,681,566, a copy of which is enclosed. There is no equivalent application in English of JP 62-185029. Applicants enclose an abstract in English of JP 62-185029. Applicants also enclose an abstract for PCT Publication No. 92/01002 A1.

Applicants also bring to the attention of the Examiner the following copending United States Patent Applications:

08/116,260	filed	9/2/93
08/375,242	filed	1/19/95
08/383,676	filed	2/1/95
08/477,638	filed	6/7/95
08/477,639	filed	6/7/95
08/482,284	filed	6/7/95
08/484,307	filed	6/7/95
08/484,312	filed	6/7/95
08/484,337	filed	6/7/95
08/484,783	filed	6/7/95

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Thomas D. Zindrick  
Attorney/Agent for Applicant  
Registration No.: 32,185  
Phone: (805) 447-8101  
Date: December 15, 1999

Please send correspondence pertaining to this application to:

U.S. Patent Operations/TDZ  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, CA 91320-1799